Overview
- 54 inspections across 53 sites are on record.
- 148 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2023-09-22.
At a glance
Inspections
54
Sites
53
Observations
148
Career since
Apr 2015
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Chongqing Biocare Pharmaceutical Ltd. | 22 Sep 2023 | Human Drugs | On file |
| Chengdu Suncadia Medicine Co., Ltd. | 15 Sep 2023 | Human Drugs | |
| Chengdu Shengnuo Biopharm Co., Ltd. | 8 Sep 2023 | Human Drugs | On file |
| Premier Pharmacy Labs Inc | 12 Jun 2019 | Human Drugs | View 483 → |
| NIH Clinical Center Pharmacy Department | 6 Mar 2019 | Human Drugs | On file |
Sites inspected
Chongqing Biocare Pharmaceutical Ltd.Chongqing, China1 insp.
Chengdu Suncadia Medicine Co., Ltd.Chengdu, China1 insp.
Chengdu Shengnuo Biopharm Co., Ltd.Chengdu, China1 insp.
Premier Pharmacy Labs IncWeeki Wachee, United States1 insp.
NIH Clinical Center Pharmacy DepartmentBethesda, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Jai P Singh5 shared
Stacie A Woods3 shared
Gam S Zamil3 shared
Alan P Kurtzberg3 shared
Qin Xu2 shared
Ruo H Xu2 shared
Darren S Brown2 shared
Truong X Nguyen2 shared
Trushani T Desai2 shared
Roger F Zabinski2 shared
Full investigator report
Get the verbatim findings behind Djamila Harouaka's 148 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site